Top-cited psoriasis authors in 4 high-impact dermatology journals: 2000-2012.
Top-cited psoriasis authors in 4 high-impact dermatology journals: 2000-2012. Dermatol Online J. 2016;22(8) Authors: Reddy S, Vu C, Choi YM, Wu JJ Abstract Psoriasis is a largely researched topic with abundant potential for publication in dermatologic journals. We used the Thomson Reuters' Web of Science citation database using the search term "psoriasis" in the titles of any literature published in 4 high-impact dermatology journals. We compiled a ranking of the top 25 cited first authors and top 25 cited authors overall on the subject of psoriasis between 2000-2012. We hope our analysis highlights the achievements of our colleagues and predecessors. PMID: 27617948 [PubMed - as supplied by publisher]
In this report, we describe a case of a patient with a clinical history of systemic sarcoidosis and psoriasis who developed biopsy-confirmed perforating and necrotizing cutaneous granulomas after 12 months of treatment with adalimumab, a tumor necrosis factor-alpha–inhibiting, anti-inflammatory, biologic medication, prescribed for the patient's psoriasis. Although rare reports of a “sarcoidosis-like” reaction associated with select tumor necrosis factor-alpha agents exist, to the best of our knowledge, perforating and necrotizing cutaneous granulomas after treatment with adalimumab has not been previously...
Publication date: 5 October 2019Source: International Journal of Pharmaceutics, Volume 569Author(s): Mahdiyeh Bahramizadeh, Maryam Bahramizadeh, Bita Kiafar, Amir Hossein Jafarian, Amin Reza Nikpoor, Mahdi Hatamipour, Habibollah Esmaily, Zari Rezaeemehr, Shiva Golmohammadzadeh, Seyedeh Alia Moosavian, Mahmoud Reza JafariAbstractThe aim of this study was to prepare and characterize topical methotrexate (MTX) with different percentages (0.05%, 0.1%, 0.25% and 0.5%) entrapped in deformable liposomes using phosphatidylcholine and oleic acid. The effectiveness and sub-acute toxicity of these topical formulations were investigat...
Background: Scalp psoriasis is usually refractory to treatment. Excimer devices proved to be a promising therapeutic option in psoriasis. Greater efficacy of phototherapy can be achieved by a concurrent use of coal tar derivatives.
Introduction: Hidradenitis suppurativa (HS) and psoriasis have been linked to cardiovascular disease. There is currently a deficiency in the literature regarding the prevalence of clinically important cardiovascular diseases that arise in patients with HS in a United States population. We sought to determine the odds of stroke, coronary artery disease (CAD), heart failure (HF), and peripheral artery disease (PAD) in patients with HS compared with patients with psoriasis and controls.
Introduction: Hidradenitis suppurativa (HS) and psoriasis has been linked to cardiovascular disease. There is currently a deficiency in the literature regarding the prevalence of clinically important cardiovascular diseases that arise in patients with HS in a United States population. We sought to determine the odds of stroke, coronary artery disease (CAD), heart failure (HF), and peripheral artery disease (PAD) in patients with HS compared with patients with psoriasis and controls.
Background: The Auspitz sign, traditionally considered a characteristic feature of psoriasis, consists of pinpoint dotted bleeding, ensuing after scratching off the outer scales, due to the rupture of twisted, dilated, superficial capillaries. Modern noninvasive techniques that may enhance the diagnosis of psoriasis include videodermatoscopy (VD) and reflectance confocal microscopy (RCM). The aim of this study was to provide a comparison between VD, RCM, and horizontal histopathological sections of the psoriatic plaques showing the Auspitz sign.
Introduction: Patients with psoriasis have lowered QoL and are especially at risk of social stigmatization and discrimination. Only few studies have investigated the impact on the QoL of partners of psoriasis patients.
Background: To better understand the relationship between physician-reported measures of disease severity and patient-reported signs and symptoms of psoriasis, an analysis was conducted from clinical trials of brodalumab, a fully human anti –interleukin-17 receptor A monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis.
This study further characterizes the associated impact of this PSP on outcomes among ADA-treated adults with psoriasis (PsO) in Europe.
Background: Apremilast is an oral phosphodiesterase 4 inhibitor approved for treatment of psoriasis and psoriatic arthritis (PsAs). The aim of this study was to evaluate the efficacy and safety of apremilast in a real-life cohort of patients with plaque psoriasis.